Literature DB >> 20624942

Cbl-b(-/-) T cells demonstrate in vivo resistance to regulatory T cells but a context-dependent resistance to TGF-beta.

Catherine O Adams1, William J Housley, Sourojit Bhowmick, Robert E Cone, Thiruchandurai V Rajan, Faripour Forouhar, Robert B Clark.   

Abstract

Cbl-b is an E3 ubiquitin ligase that negatively regulates T cell activation. Cbl-b(-/-) mice develop spontaneous autoimmunity, and Cbl-b dysregulation has been described in both murine and human autoimmune diseases. Although the mechanisms underlying the development of autoimmunity in Cbl-b(-/-) mice are not yet clear, we have reported that Cbl-b(-/-) CD4(+)CD25(-) effector T cells (Teffs) are resistant to CD4(+)CD25(+) regulatory T cell (Treg)-mediated suppression in vitro and have suggested that this may be an important mechanism in the development of autoimmunity. To confirm the relevance of this resistance to autoimmune disease, we now show that Cbl-b(-/-) Teffs are resistant to suppression by Tregs in vivo and that this involves a resistance of truly naive Cbl-b(-/-) Teffs. Additionally, we show that Cbl-b(-/-) Tregs are fully functional in vivo, further suggesting that the regulatory abnormalities in Cbl-b(-/-) mice are related to defects in Teff, not Treg, function. To characterize the relevance of TGF-beta sensitivity in Treg resistance, we examined in vivo Th17 generation and report that Cbl-b(-/-) mice are able to mount a normal Th17 response in vivo. As Cbl-b(-/-) Teffs have been shown to be insensitive to the suppressive effects of TGF-beta in other in vivo models, the present results suggest that Cbl-b(-/-) Teffs demonstrate a context-dependent sensitivity to TGF-beta in vivo. Overall, our results suggest that resistance to Tregs may be a bona fide mechanism underlying autoimmunity and that Cbl-b(-/-) mice offer unique approaches for studying the interrelationships between Treg function, TGF-beta-mediated responses, and the development of autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20624942     DOI: 10.4049/jimmunol.1001171

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720.

Authors:  Mai Fujiwara; Emily J Anstadt; Kamal M Khanna; Robert B Clark
Journal:  Clin Immunol       Date:  2015-03-28       Impact factor: 3.969

2.  Lys63-polyubiquitination by the E3 ligase casitas B-lineage lymphoma-b (Cbl-b) modulates peripheral regulatory T cell tolerance in patients with systemic lupus erythematosus.

Authors:  J Romo-Tena; S Rajme-López; L Aparicio-Vera; J Alcocer-Varela; D Gómez-Martín
Journal:  Clin Exp Immunol       Date:  2017-10-19       Impact factor: 4.330

Review 3.  Ubiquitous points of control over regulatory T cells.

Authors:  Fan Pan; Joseph Barbi
Journal:  J Mol Med (Berl)       Date:  2014-04-29       Impact factor: 4.599

Review 4.  Regulation of the transforming growth factor β pathway by reversible ubiquitylation.

Authors:  Mazin A Al-Salihi; Lina Herhaus; Gopal P Sapkota
Journal:  Open Biol       Date:  2012-05       Impact factor: 6.411

Review 5.  E3 ubiquitin ligase Casitas B lineage lymphoma-b and its potential therapeutic implications for immunotherapy.

Authors:  D Jafari; M J Mousavi; S Keshavarz Shahbaz; L Jafarzadeh; S Tahmasebi; J Spoor; A Esmaeilzadeh
Journal:  Clin Exp Immunol       Date:  2021-01-10       Impact factor: 5.732

Review 6.  Modulation of Immune Cell Functions by the E3 Ligase Cbl-b.

Authors:  Christina Lutz-Nicoladoni; Dominik Wolf; Sieghart Sopper
Journal:  Front Oncol       Date:  2015-03-11       Impact factor: 6.244

Review 7.  Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression.

Authors:  Emily R Mercadante; Ulrike M Lorenz
Journal:  Front Immunol       Date:  2016-05-18       Impact factor: 7.561

8.  Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation.

Authors:  Mai Fujiwara; Emily J Anstadt; Robert B Clark
Journal:  Front Immunol       Date:  2017-01-26       Impact factor: 7.561

Review 9.  Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.

Authors:  Xiaoli Hu; Jing Wang; Man Chu; Yi Liu; Zhi-Wei Wang; Xueqiong Zhu
Journal:  Mol Ther       Date:  2021-01-01       Impact factor: 11.454

Review 10.  Key role for ubiquitin protein modification in TGFβ signal transduction.

Authors:  Miriam De Boeck; Peter ten Dijke
Journal:  Ups J Med Sci       Date:  2012-02-15       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.